Senores Pharmaceuticals has announced a comprehensive warrant issuance program following board approval at its meeting held on January 07, 2026. The pharmaceutical company has received authorization for issuing convertible equity warrants worth ₹950.04 crores, representing a significant capital mobilization initiative targeting promoter and promoter group entities.

Warrant Issuance Specifications

The board has structured a detailed warrant offering with specific parameters for potential investors. The preferential issue involves fully convertible equity warrants that provide holders the right to subscribe to equity shares within a defined timeframe.

Investor Details and Shareholding Impact

The warrant issuance targets five specific investors from the promoter and promoter group category. The allocation demonstrates strategic capital infusion from existing stakeholders, with varying investment commitments across different entities.

Payment Structure and Conversion Terms

The warrant structure follows regulatory guidelines with a phased payment mechanism. Warrant holders must pay 25% of the exercise price at allotment, with the remaining 75% payable upon conversion to equity shares. Each warrant carries the right to subscribe to one equity share of ₹10.00 face value.

The conversion window extends for 18 months from the allotment date, providing flexibility for warrant holders to exercise their rights based on market conditions. Unconverted warrants will automatically lapse after the exercise period, with amounts paid being forfeited.

Corporate Governance and Regulatory Compliance

The board has established January 01, 2026, as the relevant date for determining the floor price under SEBI ICDR Regulations. An Extraordinary General Meeting has been scheduled for January 31, 2026, at 12:30 PM through video conferencing to obtain shareholder approval for the preferential issue.

The company has appointed M/s. Mukesh H. Shah & Co., Practicing Company Secretaries, as scrutinizer for the e-voting process. The cut-off date for EGM notice dispatch has been fixed as January 02, 2026, ensuring compliance with regulatory timelines and transparency requirements.

Senores Pharmaceuticals has received a significant GST demand order from the Central Goods & Service Tax Authority, as disclosed in a regulatory filing. The pharmaceutical company informed stock exchanges about receiving a demand order that could impact its financial obligations.

GST Demand Details

The Central GST Authority has issued a demand order in Form GST DRC-07 with substantial financial implications for the company:

The order was received by the company from the Office of the Deputy/Assistant Commissioner, Central Goods & Service Tax & Central Excise, Ahmedabad-North.

Nature of Alleged Violations

The GST demand stems from specific compliance issues identified by the tax authorities:

• Alleged non-reversal of excess Input Tax Credit
• Alleged non-payment of Integrated Goods and Services Tax (IGST)

These violations relate to the company's GST compliance procedures and tax credit management processes during the period under scrutiny.

Company's Response and Impact Assessment

Senores Pharmaceuticals has outlined its strategy to address the demand order. The company is preparing to file an appeal before the GST Commissioner (Appeals) based on the merits of the case. Management has assessed the potential impact on various aspects of the business:

Regulatory Compliance

The disclosure was made under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates listed companies to inform stock exchanges about material events that could affect their business operations or financial position.

The company's management remains confident about the appeal process and expects to successfully contest the demand based on the case's merits. This regulatory disclosure ensures transparency with shareholders and the investment community regarding potential financial obligations.